Immune profiling of respiratory viruses in vulnerable people
Official title: Systems Immunology profiling of respiratory viral infections in vulnerable populations
Funded at Benaroya Research Inst at Virginia Mason · NIH-11332436 · Data updated 2026-11-12
This project maps how the immune system responds to respiratory viruses in people who are especially at risk, using samples like nasal swabs and blood.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | March 29, 2022 |
| Project end | February 28, 2027 |
| Funding year | 2026 |
| Award (this year) | $326,266 |
| NIH project number | 5U19AI167891-05 |
| Project ID | NIH-11332436 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people who get respiratory viral infections and are considered vulnerable (for example young children or adults at higher risk) who can provide nasal, sputum, and blood samples.
✕Less likely to help
People without respiratory infections, those not in the targeted vulnerable groups, or anyone unwilling to provide the required samples are unlikely to be included or to benefit directly.
What this research studies
You would provide nasal swabs, blood draws, and sputum samples when you have a respiratory viral infection. The Genomics Core will run bulk RNA sequencing and single-cell proteogenomic sequencing to see which genes and proteins immune cells make and to read T and B cell receptor sequences. For very rare antigen-specific cells they will sort cells into plates for sequencing, and for larger cell populations they will use 10X single-cell immune profiling with TotalSeq to measure gene expression, surface markers, and receptor clonotypes. The data will be combined so researchers can link related cells and better understand immune responses during infection.
Why it matters
Potential benefit: If successful, the work could help identify immune patterns that lead to severe illness and guide better diagnostics, vaccines, or treatments for at-risk people.
How similar studies have gone: Single-cell and bulk sequencing methods have already improved understanding of immune responses in other settings, though applying them specifically to vulnerable populations is a more recent effort.
Where this research is happening
-
Benaroya Research Inst at Virginia Mason
Seattle, United States Active
Researchers
- Principal investigator: Linsley, Peter S — Benaroya Research Inst at Virginia Mason
- Study coordinator: Linsley, Peter S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.